 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
| «12...345678910111213...1718» |
- ||||| Tecvayli (teclistamab) / Genmab, J&J, talquetamab (JNJ-64407564) / J&J
Review: Hot off the press in Multiple Myeloma: The magnificent Dr. Rachid Baz review the data from MajesTEC-1 (Teclistimab trial in RRMM) and MonumenTAL-1 (Talquetamab trial in RRMM). @MoffittNews @MoffittHemOnc @MoffittResearch (Twitter) - Jan 28, 2023
- || Tecvayli (teclistamab) / Genmab, J&J
Wait for frontline Teclistamab data .. (Twitter) - Jan 27, 2023
- |||| Tecvayli (teclistamab) / Genmab, J&J
🚨 CORRECTION: After a helpful tip from Janssen, I found this helpful gem on page 90 of the EMA's assessment report: Teclistamab is a modified IgG lambda mAb, not kappa, and how it affects SIFE is not yet fully characterized. More mysteries to solve! https://t.co/IuYCODt4dX https://t.co/0ntjBPmaLF (Twitter) - Jan 27, 2023
- |||| Tecvayli (teclistamab) / Genmab, J&J
🚨 CORRECTION: After a helpful tip from Janssen, I found this helpful gem on page 90 of the EMA's assessment report: Teclistamab is a modified IgG lambda mAb, not kappa, and how it affects SIFE is not yet fully characterized. More mysteries to solve! https://t.co/IuYCODt4dX (Twitter) - Jan 27, 2023
- |||| Tecvayli (teclistamab) / Genmab, J&J
Discussing the #hot bispecific cell engagers to treat #multiplemyeloma @OncLive @OncLiveSOSS @SandyWong02111 approval of teclistamab big due to huge area of need as it’s an off the shelf option @UCSFCancer with chair @TomBmt133 (Twitter) - Jan 26, 2023
- |||| Tecvayli (teclistamab) / Genmab, J&J
Why hello there, teclistamab!! (At least this is what I'm presuming - has anyone seen subQ tec show up on SIFE dara-style in #MMsm)? (Twitter) - Jan 25, 2023
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J
New P2 trial, Combination therapy: GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (clinicaltrials.gov) - Jan 25, 2023
P2, N=50, Recruiting, Sponsor: University of Heidelberg Medical Center
- Tecvayli (teclistamab) / Genmab, J&J
Case Presentation (MM): Sequential Therapy with Teclistamab after Failure of BCMA-directed CAR-T Therapy (Breakout room, Hybrid) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_262;
- || Kimmtrak (tebentafusp) / Immunocore, Medison, Tecvayli (teclistamab) / Genmab, J&J
Letztes Jahr wurde Tebentafusp für das Aderhautmelanom zugelassen und Teclistamab steht zur Behandlung des Multiplen Myeloms kurz vor der Einführung. (Twitter) - Jan 22, 2023
- || Tecvayli (teclistamab) / Genmab, J&J, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
My SIL is hovering in this space … refractory to nearly all standards, been waiting (on Selinexor 🤯) for Teclistamab, now advised that her treatment center wants to enroll her in a trial for something else. She’s not enthused. Impressive institution & authors of that paper. (Twitter) - Jan 19, 2023
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J
Enrollment closed: MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov) - Jan 18, 2023
P1b, N=140, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting
- | Tecvayli (teclistamab) / Genmab, J&J
Journal: Teclistamab-cqyv. (Pubmed Central) - Jan 17, 2023
Recruiting --> Active, not recruiting No abstract available
- |||| lenalidomide / Generic mfg., Darzalex (daratumumab) / J&J, Tecvayli (teclistamab) / Genmab, J&J
Teclistamab Plus Daratumumab/Lenalidomide Generates Responses in Relapsed/Refractory Myeloma @DrEmmaSearle @TheChristieNHS @OfficialUoM @ASH_hematology #mmsm #ASH22 https://t.co/RccfngNu8x (Twitter) - Jan 13, 2023
- ||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: But one guess might be whether the study explore inpatient vs. outpatient treatment. I didn't treat anyone on teclistimab study, but NEJM paper says inpatient only I think? Mosun trial pivoted to outpatient (and subQ, coming soon hopefully) very successfully. (Twitter) - Jan 4, 2023
- || Tecvayli (teclistamab) / Genmab, J&J
Even though the rates of Gr3+ CRS are similarly very low, teclistimab definitely had more CRS (~70% vs. ~45%), happened into cycle 2 more often, required more toci (~35% vs. 20%). Why these differences translated into REMS vs. no REMS, I don't know... (Twitter) - Jan 4, 2023
- ||| Tecvayli (teclistamab) / Genmab, J&J, Lunsumio (mosunetuzumab) / Roche, Biogen
Clinical: Does anyone have insight into why FDA put a REMs program and hospital admin requirement on teclistimab but not mosunetuzumab? Toxicities looks fairly similar to me on first look. (Twitter) - Jan 3, 2023
- || Tecvayli (teclistamab) / Genmab, J&J
Are you going to do Teclistamab in your practice Rohit? (Twitter) - Jan 3, 2023
- ||| Tecvayli (teclistamab) / Genmab, J&J
2/ Other nuance will be what to do if someone is on C8 of Tecvayli but misses 3 weeks’ worth of dosing due to an infection (say, COVID) and recovery. Will they go back to the academic center for a repeat step-up dosing admission? (No easy answer!) (Twitter) - Jan 2, 2023
- |||| lenalidomide / Generic mfg., Darzalex (daratumumab) / J&J, Tecvayli (teclistamab) / Genmab, J&J
Combination therapy: Findings from the phase 1b MajesTEC-2 trial indicated that teclistamab in combination with daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma. #mmsm | @DrEmmaSearle https://t.co/0ei9Ns3Lnb (Twitter) - Jan 1, 2023
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: Yes indeed - super exciting! For the #MMsm bsAb teclistamab, I'll clarify that the actual approval is for 4+ prior lines and not 3+. But MajesTEC enrolled 3+ lines of therapy, right? Yes indeed, as did KarMMa and CARTITUDE-1... but FDA gets to make its own rules as it goes 🤷♂️ (Twitter) - Dec 31, 2022
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Tecvayli (teclistamab) / Genmab, J&J, Imfinzi (durvalumab) / AstraZeneca
4-… -Ameliyat edilemeyen ileri evre hepatoselüler karsinom (karaciğer kanseri) için tremelimumab (Imjudo) artı durvalumab (Imfinzi). -Nükseden/dirençli multipl miyelomda kullanım için bispesifik bir B hücresi antijeni (BCMA) CD3 antikoru olan teclistamab-cqyv (Tecvayli). (Twitter) - Dec 29, 2022
- | Tecvayli (teclistamab) / Genmab, J&J, Talvey (talquetamab) / J&J
Trial completion date: RedirecTT-1: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 29, 2022
P1b, N=102, Recruiting, Sponsor: Janssen Research & Development, LLC
No abstract available Trial completion date: May 2024 --> Feb 2025
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date: MajesTEC-1: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 29, 2022
P2, N=244, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: May 2024 --> Feb 2025 Trial completion date: Dec 2024 --> May 2025
- ||| lenalidomide / Generic mfg., Darzalex (daratumumab) / J&J, Tecvayli (teclistamab) / Genmab, J&J
Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma. #mmsm #ASH22 | @DrEmmaSearle @OfficialUoM https://t.co/8eIt9wdBsI (Twitter) - Dec 27, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: Thomas G. Martin, MD, discusses the goals and efficacy outcomes of the phase 1/2 MajesTEC-1 trial of teclistamab-cqyv for patients with relapsed/refractory multiple myeloma. #mmsm | @UCSFCancer @TomBmt133 https://t.co/nR8BtwUE8D (Twitter) - Dec 26, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
6. MAJESTEC-1 (NEJM August 2022) Teclistamab is active in relapsed/refractory myeloma (N=165, response=63%,PFS=11 months). Toxicity non-trivial, concerned about use in frail population up-front, but great to have this option available off-the shelf. https://t.co/naBoZ4bXdW (Twitter) - Dec 23, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J, Carvykti (ciltacabtagene autoleucel) / J&J
In 2022 we had two more new treatments approved for myeloma: cilta-cel (CAR-T therapy) and teclistamab (BCMA bispecific). We are making steady progress. #MedTwitter (Twitter) - Dec 21, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
This thread is long, but so important to grasp. We will likely see the same issues repeated in up-front teclistamab trials (MAJESTEC-7) where there is no cross-over or specific post-protocol access plans built in (to best of my knowledge). (Twitter) - Dec 19, 2022
- ||||| Tecvayli (teclistamab-cqyv) / Genmab, J&J
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: MajesTEC-4: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (clinicaltrials.gov) - Dec 13, 2022
P3, N=1500, Recruiting, Sponsor: European Myeloma Network
Trial completion date: Dec 2024 --> May 2025 N=1000 --> 1500 | Trial completion date: Nov 2032 --> Dec 2031 | Trial primary completion date: Aug 2027 --> Oct 2028
- || Tecvayli (teclistamab) / Genmab, J&J
that's interesting to see how the class swith to teclistamab was efficient initially, and how faster the slope is on the Lamba curve on relapse along time (Twitter) - Dec 13, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
Breakfast TV #ASH22, excellent presentation and considered responses on emerging role of teclistamab by the excellent @DrEmmaSearle (Twitter) - Dec 11, 2022
- || Tecvayli (teclistamab) / Genmab, J&J
Prob start Teclistamab (Twitter) - Dec 11, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: With Teclistamab & other #BiSAb coming to practice, and growing #CART indications, we need to expand outpatient capabilities to ensure patient access. Come here the latest data @MayoCancerCare on Monday #ASH22 #lymsm #mmsm @MayoKernScholar @jhalamka (Twitter) - Dec 11, 2022
- ||| Tecvayli (teclistamab) / Genmab, J&J
This is why I think the labels that the Roche bispecs will have are going to be more important, as they are fixed duration treatments. Currently, both epco in NHL and tecvayli/teclistamab in MM are treat till progression (Twitter) - Dec 11, 2022
- ||| lenalidomide / Generic mfg., Darzalex (daratumumab) / J&J, Tecvayli (teclistamab) / Genmab, J&J
Findings from the phase 1b MajesTEC-2 trial showed that teclistamab plus with daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma. #mmsm #ASH22 | @ASH_hematology @DrEmmaSearle https://t.co/yBaWLvgqeM (Twitter) - Dec 11, 2022
- | Tecvayli (teclistamab) / Genmab, J&J
But it didnt mean that with teclistamab (Twitter) - Dec 11, 2022
- ||||| lenalidomide / Generic mfg., Darzalex (daratumumab) / J&J, Tecvayli (teclistamab) / Genmab, J&J
Clinical, P1 data: CONGRESS | #ASH22 Emma Searle @DrEmmaSearle, @OfficialUoM presents initial data from the ongoing phase Ib MajesTEC-2 trial, showing that the addition of teclistamab to daratumumab and lenalidomide is well tolerated and shows promising clinical activity in patients with MM. #mmsm (Twitter) - Dec 10, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J
Minimal residual disease: Rub some ‘DRT’ on it. MajesTEC-2 with Dara/Len/Tec. ORR 93.5% in a less refractory population with high rates of CR (55%). No data on mrd negativity among the CR population. But definitely makes a case for combination strategies for teclistamab. #ash22 #mmsm (Twitter) - Dec 10, 2022
- ||||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: Although I am super excited about teclistamab combinations in earlier lines of therapy, 6.25% fatal AEs 2/2 infection in Dara-Tec-Len is concerning. Need to develop new strategies to mitigate infection risk such that greater efficacy is not neutralized by high tox. #ASH22 #mmsm (Twitter) - Dec 10, 2022
- | Journal: Antibodies and bispecifics for multiple myeloma: effective effector therapy. (Pubmed Central) - Dec 10, 2022
Currently, teclistamab, an anti-BCMA bispecific, is closest to approval for commercial use. In this review, we explore the evolving landscape of antibodies in the treatment of MM, including their role in frontline and relapse settings.
- ||||| Tecvayli (teclistamab) / Genmab, J&J
Clinical: If patients still have detectable BCMA following BCMA treatment, treating with a second BCMA therapy is possible. Examples include elrantanamab and teclistamab studies. #HealthTreeMM #ASH22 #mmsm @IreneGhobrial (Twitter) - Dec 9, 2022
- || Tecvayli (teclistamab) / Genmab, J&J
What’s the “management that helps?” She hasn’t had it. It’s just suffering in hopes of something better, eg Teclistamab. (Twitter) - Dec 9, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Clinical: Just living with #myeloma means you are tough as nails, both patient and caregiver. Yes, #selinexor has SEs for some/many, management can help continuation of treatment that keeps #myeloma at bay. Same will be true for #teclistamab. (Twitter) - Dec 9, 2022
- || Tecvayli (teclistamab) / Genmab, J&J, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Whoa. A lot of heme-oncs will barely if at all prescribe Selinexor. My SIL has been on a weekly triplet regimen with it for quite some time. And it ruins half the week. She’s miserably sick from it. Not sure what “manage toxicity” means here. She’s waiting for Teclistamab. (Twitter) - Dec 9, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: Teclistamab is the first FDA-Approved BCMA-Targeted Bispecific Antibody in adults with relapsed refractory myeloma after >4 lines of therapy @BerdejaJesus #ASH22 #mmsm (Twitter) - Dec 9, 2022
- |||| Tecvayli (teclistamab) / Genmab, J&J
Si los pacientes todavía tienen BCMA detectable despúes del tratamiento BCMA, se puede volver a tratar con un segundo BCMA. Tenemos por ejemplo la terapia con elrantanamab y teclistamab. #HealthTreeMM #ASH22 #mieloma @IreneGhobrial (Twitter) - Dec 9, 2022
- || Tecvayli (teclistamab) / Genmab, J&J
And I should add - just as quadruplets are better than doublets, if we can get q4wk bsAb dosing in due time (happening with teclistamab in MajesTEC-3 and MajesTEC-7 over time)... that would be amazing!! (Twitter) - Dec 9, 2022
- | Tecvayli (teclistamab) / Genmab, J&J
Journal: Teclistamab for the treatment of multiple myeloma (Pubmed Central) - Dec 9, 2022
In this review, we explore the evolving landscape of antibodies in the treatment of MM, including their role in frontline and relapse settings. No abstract available
- ||||| Tecvayli (teclistamab) / Genmab, J&J
FDA event: Teclistamab is the first FDA-approved bispecific antibody for MM and @DoctorAKrishnan reviews the MajesTEC-1 study data #RMELiveMM #mmsm #ASH22 (Twitter) - Dec 9, 2022